Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy

Journal of Gastroenterology

Volumn 39, Issue 5, 2004, Pages 455-460

  Arase, Yasuji ^a   Ikeda, Kenji ^a   Tsubota, Akihito ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Kobayashi, Masahiro ^a   Suzuki, Fumitaka ^a   Akuta, Norio ^a   Someya, Takashi ^a   Hosaka, Tetsuya ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Biochemical response; Chronic hepatitis C; Interferon retreatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; LYMPHOBLAST INTERFERON;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DYSFUNCTION; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RELAPSE; RETREATMENT; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VIRUS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETREATMENT;

EID: 3042565569     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1323-4     Document Type: Article

References (34)

1. Tsubota A, Chayama K, Arase Y, Koida I, Saitoh S, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
2. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology 1992; 15:37-41.
3. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double blind placebo-controlled trial. N Engl J Med 1989;321:1506-10.
4. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 1991;101:497-502.
5. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-3.
6. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, et al. Two-year biochemical, virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995;21:918-22.
7. Yoshioka K, Yano M, Kusakabe A, Hirofuji H, Fuji A, Kuriki J, et al. Randomized controlled trial of lymphoblastoid interferon α for chronic hepatitis C. Am J Gastroenterol 1999;94:164-8.
8. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653-9.
9. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. New Engl J Med 1997;336:347-56.
10. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995;21:291-7.
11. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113: 558-66.
12. Suzuki H, Tango T, Consensus Interferon Group. A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Hepatol Res 2002;22: 1-12.
13. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk of hepatocellular carcinoma. Ann Intern Med 1999;131:174-81.
14. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
15. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-9.
16. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
17. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930-8.
18. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-72.
19. Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Nakamura I, et al. Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy. J Gastroenterol 1999;34:594-9.
20. Detmer J, Lagier R, Flynn J, Zayati C, Kolberg, Collins M, et al. Accurate quantification of hepatitis C virus (HCV) RNA from HCV-genotypes by using branched-DNA technology. J Microbiol 1996;34:901-7.
21. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993;18:16-20.
22. Hashimoto M, Chayama K, Tsubota A, Kobayashi M, Nakano A, Takagi K, et al. Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequences of NS5 region. Int Hepatol Commun 1996;4:263-7.
23. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
24. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;32:1457-62.
25. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2b for 60 weeks. Hepatology 1994;19:280-5.
26. Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F, et al. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon 2b for chronic hepatitis type C. J Hepatol 1997;27:56-62.
27. Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, et al. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J Gastroenterol 2003;38:158-63.
28. McHuchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
29. Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
30. Reichard O, Norkrans G, Fryden A. Randomised, double-blind, placebo controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7.
31. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997;26:961-6.
32. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai My, Gane E, et al. Peginterferon α-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
33. Lindsay KL, Trepo C, Heintges T, Shiffmann ML, Gordon SC, Hoefs JC, et al. A randomized, doubled-blinded trial comparing pegylated interferon α-2a to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
34. Nishiguchi S, Tanaka M, Shiomi S, Kaneshiro S, Enomoto M, Fukada K, et al. Changes in hypervariable region 1 in patients with chronic hepatitis C of genotype 1b with biochemical response to interferon. Hepatol Res 2002;23:237-50.